News

Phase 2 Trial Data Show Therapeutic Benefits of Investigational Cannabidiol Gel ZYN002 in Children with Fragile X Syndrome

Zynerba Pharmaceuticals’ investigative therapy ZYN002 — a pharmaceutically produced cannabidiol (CBD) gel — was seen to significantly improve behavioral symptoms in children and adolescents with fragile X syndrome (FXS), according to new Phase 2 clinical data. “These data are consistent and compelling, and suggest that ZYN002 may have a clinically…